Plerixafor in Chinese Patients with Non-Hodgkin Lymphoma, a Pharmacokinetics and Pharmacodynamic study

Trial Profile

Plerixafor in Chinese Patients with Non-Hodgkin Lymphoma, a Pharmacokinetics and Pharmacodynamic study

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2015

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 27 Jul 2015 New trial record
    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top